Biotech Startups

CollaMedix develops collagen-based medical devices and biomaterials manufacturing technologies using an electrocompaction process licensed from Case Western Reserve University, including an electrocompacted collagen sling for female pelvic health. Its products target soft tissue repair and augmentation for clinicians, providers, and industry partners.

1 investor

CollPlant is a regenerative medicine company that develops plant-derived type I recombinant human collagen (rhCollagen) and related biomaterials for tissue regeneration, organ manufacturing, and medical aesthetics. Its technologies support 3D bioprinting of tissues and organs, dermal fillers, soft tissue repair, and drug discovery models.

1 investor

Colorado Health Impact is an economic development initiative promoting Colorado as a location for life sciences companies, highlighting the state's medtech, biotech, pharmaceutical, and digital health clusters along the Front Range. It offers relocation and expansion support to companies through the Colorado BioScience Association and the Metro Denver Economic Development Corporation.

1 investor

1 investor

CompagOs develops Bon3OID, a biohardware platform that combines 3D bioprinted bone-like tissue constructs with hardware for controlled mechanical loading to produce functional readouts of bone remodeling. It serves preclinical drug development and translational diagnostics as a human-relevant in-vitro alternative to animal models for bone-focused research.

1 investor

Complete Omics develops a clinical proteomics platform that identifies patient-specific neoantigens to enable personalized cancer therapeutics. The platform guides the design of targeted treatments such as mRNA vaccines and cell therapies.

1 investor

Complyit is a specialist consulting firm in the life sciences sector, providing services such as project management, quality assurance, and validation for the pharmaceutical and medical technology industries. It supplies experienced consultants to companies with high requirements on staff knowledge and expertise.

1 investor

A blood bank and laboratory services provider supplying blood products including red blood cells, plasma, and platelets to hospitals and medical facilities, alongside laboratory testing services and specialty clinical procedures. Serves medical institutions, research facilities, and pharmaceutical companies nationally.

1 investor

Compugen develops immuno-oncology therapeutics using Unigen, a computational platform that combines scientific research with AI/ML to identify novel drug targets and design first-in-class antibody drugs. Its therapeutic antibodies targeting novel pathways are being evaluated in multiple clinical trials.

1 investor

1 investor

Conception Nurseries produces tissue culture micropropagated cannabis clones that are pest-free, disease-free, and genetically verified for commercial cannabis cultivators. The company applies proprietary biotechnology to enable scaled production of cannabis genetics while maintaining quality standards.

1 investor

Concinnity Genetics develops control mechanisms to improve the safety of cell and gene therapies, using an AI platform and synthetic biology to help biopharmaceutical partners design and optimise their gene therapies. Spun out of the University of Edinburgh in 2023, it serves gene therapy developers in the biopharmaceutical industry.

1 investor

Conexeu is developing CXU™, a collagen-based extracellular matrix (ECM) platform for soft-tissue regeneration intended as an alternative to static fillers, combining structural support with tissue in-growth and integration. The platform is positioned as a single formula and device with potential use across a range of human and animal regenerative medicine applications.

1 investor

Confience delivers a cloud-based Laboratory Information Management System (LIMS) for environmental, food and beverage, pharmaceutical, and industrial laboratories to eliminate manual data entry, maintain regulatory compliance, and ensure traceability from sample receipt to result delivery. The platform includes integrated field data collection, client portals, and direct instrument integration to reduce manual work and transcription errors.

1 investor

Confluence Discovery Technologies is a full-service drug discovery contract research organization (CRO) that partners with pharma and biotech companies across cell and molecular biology, biochemistry, enzymology, immunology, in vivo efficacy, and medicinal chemistry. It focuses on complex biological systems, challenging drug targets, immuno-oncology, and preclinical and clinical biomarker development.

1 investor

Confluence Genetics develops proprietary soybean varieties using an AI-driven breeding platform called CropOS® to deliver improved yields and quality traits. The company serves farmers and grain industry partners across the U.S. agricultural supply chain.

1 investor

Confocal NL develops confocal microscopy systems for live cell and super-resolution imaging with low phototoxicity and high signal-to-noise ratios. Its systems are used by researchers for imaging applications such as multi-well plate screening, organoids, tissue samples, and model organisms.

1 investor

Connect Afya operates a clinical testing laboratory, medical device wholesale business, and clinics in Nairobi, Kenya, offering services from routine and genetic testing to pathology, including an ISO 15189-accredited lab with a next-generation sequencer. It also partners with global pharmaceutical companies and CROs on clinical trial support, IVD performance evaluation, and antimicrobial resistance diagnostics infrastructure.

1 investor

Conquest Labs builds AI models to discover and develop cancer therapies by engineering multi-drug combinations that guide biological systems from diseased to healthy states. The company integrates computational drug discovery with laboratory feedback to identify new therapeutic approaches for cancer treatment.

1 investor

Constellate uses reversibly-binding affinity probes to read antibody samples one molecule at a time, resolving critical quality attributes (titre, glycosylation, aggregation, charge) from a single drop of crude supernatant in minutes rather than weeks. The resulting single-molecule data trains predictive "world models" of cell-line behaviour for antibody developers and CDMOs doing cell-line and process development.

1 investor

Bukwang Pharm is a South Korean pharmaceutical company that develops and licenses drugs for antiviral, gastrointestinal, CNS, and metabolic disorders. The company sells primarily licensed products from Europe, the United States, and Japan.

1 investor

Continuity develops autonomous systems that continuously track dozens of blood biomarkers directly from the body without a blood draw, using a bioprotonics sensing array and AI to detect deviations and deliver real-time interventions. The company applies this physical-intelligence approach to personalized healthcare and preventive health.

1 investor

Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC). The clinical-stage biotech is advancing radiopharmaceutical treatments backed by preclinical and clinical data.

1 investor

Convergent Genomics is a genomic diagnostics company that uses next-generation sequencing and liquid biopsy to extract DNA from urine and detect, monitor, and predict urothelial (bladder) cancer non-invasively. Its test targets earlier cancer recurrence detection for clinicians and patients.

1 investor